EFEITOS TERAPÊUTICOS DOS CANABINÓIDES NA ENCEFALOPATIA TRAUMÁTICA CRÔNICA: UMA REVISÃO DA LITERATURA

Resumo

Objetivo: Avaliar as respostas terapêuticas entre os diferentes endocanabinóides no tratamento de ECT. Métodos: Realizou-se revisão narrativa com buscas nas bases PubMed, LILACS e Google Acadêmico, utilizando descritores MeSH e DeCS relacionados a traumatismo cranioencefálico (TCE), ETC e canabinóides. Incluíram-se estudos experimentais com modelos animais, humanos ou culturas celulares. Resultados: Dos 147 artigos identificados, 31 foram elegíveis. As substâncias analisadas incluíram agonistas CB1/CB2, antagonistas de NMDA e inibidores das enzimas FAAH e MAGL. Os estudos relataram reduções significativas da neuroinflamação, edema, morte neuronal e sintomas comportamentais associados à ETC. Conclusão: Os canabinóides, especialmente os agonistas CB1/CB2, demonstraram potencial terapêutico. No entanto, são necessários ensaios clínicos controlados, especialmente em TCE leve e moderado, para confirmar eficácia e segurança.

THERAPEUTIC EFFECTS OF CANNABINOIDS ON CHRONIC TRAUMATIC ENCEPHALOPATHY: A LITERATURE REVIEW

Objective: To evaluate the therapeutic responses of different endocannabinoids in the treatment of Chronic Traumatic Encephalopathy (CTE). Methods: A narrative review was conducted through searches in the PubMed, LILACS, and Google Scholar databases, using MeSH and DeCS descriptors related to traumatic brain injury (TBI), CTE, and cannabinoids. Experimental studies involving animal models, humans, or cell cultures were included. Results: Of the 147 articles initially identified, 31 met the eligibility criteria. The substances analyzed included CB1/CB2 receptor agonists, NMDA receptor antagonists, and selective inhibitors of the FAAH and MAGL enzymes. The studies reported significant reductions in neuroinflammation, cerebral edema, neuronal death, and behavioral symptoms associated with CTE. Conclusion: Cannabinoids, particularly CB1/CB2 agonists, demonstrated therapeutic potential. However, controlled clinical trials—especially in cases of mild to moderate TBI—are needed to confirm their efficacy and safety.